DOCSLIB.ORG

Opioid-Ketamine and Norketamine Codrug Combinations for Pain Management Joseph R

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Opioid-Ketamine and Norketamine Codrug Combinations for Pain Management Joseph R University of Kentucky UKnowledge Pharmaceutical Sciences Faculty Patents Pharmaceutical Sciences 4-29-2014 Opioid-Ketamine and Norketamine Codrug Combinations for Pain Management Joseph R. Holtman University of Kentucky, [email protected] Peter A. Crooks University of Kentucky, [email protected] Ujjwal Chakraborty University of Kentucky, [email protected] Right click to open a feedback form in a new tab to let us know how this document benefits oy u. Follow this and additional works at: https://uknowledge.uky.edu/ps_patents Part of the Pharmacy and Pharmaceutical Sciences Commons Recommended Citation Holtman, Joseph R.; Crooks, Peter A.; and Chakraborty, Ujjwal, "Opioid-Ketamine and Norketamine Codrug Combinations for Pain Management" (2014). Pharmaceutical Sciences Faculty Patents. 32. https://uknowledge.uky.edu/ps_patents/32 This Patent is brought to you for free and open access by the Pharmaceutical Sciences at UKnowledge. It has been accepted for inclusion in Pharmaceutical Sciences Faculty Patents by an authorized administrator of UKnowledge. For more information, please contact [email protected]. US. Patent Apr. 29, 2014 Sheet 1 017 US 8,710,070 B2 Enhancement of Morphine (MOR) Antinociception with S-Norketamine Taii~Fiick Test intraperiioneal Administration (IP) L i \ i L TAiLFUCKLATENCY(s) O) I MOR (Snig/kg) O _ Q SWNK(3mg/kg) MOR<3mg/kg)+s-NK A 0.75 v 1.5 Q 3 i i i i i 1 i FiG. 1A O 20 4O 60 80 100 120 TIME (min) Enhancement of Morphine (MOR) Antinociception with S-Norketamine (S-NK) Taii~Fiick Test intrathecal Administration (iT) HG- 1B W B * 100 [T-J S_NK 7 ? MOR 80 _ MOR + S-NK 60 ~ * / %MAXIMUMPOSSiBLEEFFECT(%MPE 40 ~ % 20 ~ additive effect 0 __*Ei__,1i...3 MGR - 3 DOSE (mg/kg; iP) Mean 11" SEM (n = 8 rats); * Different from MOR (3 mG/Ko) aione (P<0.05: Dost-hock SNK) US. Patent Apr. 29, 2014 Sheet 2 0f7 US 8,710,070 B2 Enhancement of Morphine (MOR) Antinociception with S-Norketarnine (S-NK) Taii~Flick Test lntrathecal Administration (IT) 14 ~ A Q saline MOR (O?mcg) + S-NK ’0‘; I S'NKUOOmcg) Y 10mcg V 12 ' A MOR(O.5mOQ) 0 5011109 6 ‘ 100mcg ZLu 10 5 8 ~ 6 6 " \ 3 \ u. \I d 4 u IT‘JIRT‘ ? 2 , O i i i \ i l 1"“ 0 3O 60 90 120 150 180 FiG. 2A TIME (min) Enhancement of Morphine (MOR) Antinociception with S-Norketamine (S'NK) Taii~Flick Test SJ intrathecai Administration (1T) FIG“ ZB 2 2*”, 100 » B i».. 0 mE 80 w w S-NK + MOR * LLJ @ 60 ~ / c!) U) 1: g 40 m ,1 E additive effect H :3 E 20 ~*'—"“‘“"—'* “n “Wm M "W >< ,, E<1: n c\@ O S-NK 100 ~ 10 50 100 - MOR — 0.5 0.5 0.5 0.5 30 DOSE (meg) Mean +/— SEM (n = 7-9 rats); * Different from MOR (0.5 mcg) alone (P<0.06; post/hoe SNK) US. Patent Apr. 29, 2014 Sheet 3 0f7 US 8,710,070 B2 Enhancement of Morphine (MGR) Antiallodynia with S~Norketamine (S-NK) Chronic Constriction Nerve Injury (CCi) Intraperitoneai Administration (1P) § 20 C1 , A 6 O saline MOR (1mglkg) + S—NK I [I] MOR (1mg/kg) V 2mg/kg w 15 ~ A S-NK (8mg/kg) <> 4mg/kg LU O 8mg/kg E 5 “1121 e 0 " E i i i i i i i O 20 4O 60 80 100 120 FIG. 3A TiME (min) Enhancement of Morphine (MOR) Antiaiiodynia with S-Norketamine (S-NK) Chronic Constriction Nerve Injury (CC!) HG_ 3B g? lntraperitoneai Administration (1P) <~ B >0(.3 100 .M *— ? 80 e k " E MOR + S'NK w 60 ~ _.i 99 m g 40 @— additive effect T E M~,__m__:_ W-“ .__‘_ D 20 ~ 2 >< g 0 i a? S-NK a - 2 MOR - i 1 DOSE (mg/kg) Mean +/~ SEM- * Different from MOR (1 rng/kg) alone (P<U_05; posbhcc SNK) US. Patent Apr. 29, 2014 Sheet 4 0f 7 US 8,710,070 B2 Enhancement of Morphine (MGR) Antihyperalgesia with S~Norketarnine (S—NK) Chronic Constriotion Nerve Injury (CCI) e Intraperitoneai Administration (IP) O A (—31 II MGR (3mg/kg) I 0 S-NK(1mg/kg) a 300 m MOR (Ems/k9) +' S<NK A 0.01 v 0.1 Q 1 DC I I— e g 200 ~~ 3 <1: 8 > 100 ~ poleC/_ I I I I I F‘G. O 30 60 90 120 TIME (min) Enhancement of Morphine (MOR) Antihyperaigesia with S~Norketamine (S-NK) Chronic Constriotion Nerve Injury (CCI) lntraperitoneai Administration (IP) FIG“ 4B A 120 - E MOR B E [:11 MM f $5 100 " w“ MORI-S—NK * i LU6 80 ~ & LLI * / LU 60 - 55 a '5 40 ~ . C!) O additive effect a. e-_-~___~-_ Mun“ -_W --_~_— ~-~ % 20 v 55E O m E SNK 1 - 001 0,1 1 _ $3 MOR , 3 3 3 3 1O DOSE (mg/Kg) Mean +/~ SEM * Different from MOR (3 mg/kg) alone (P<0005; post-hoe SNK) US. Patent Apr. 29, 2014 Sheet 5 0f7 US 8,710,070 B2 “M g :NFE;L 0 1HNMR US. Patent Apr. 29, 2014 Sheet 6 0f 7 US 8,710,070 B2 Nwm.-\w35/0 omion p mwohmvmmm.in"? _// wowdm; LP/528 \/ \I mwmwowmnmdmr _0zO O US. Patent Apr. 29, 2014 Sheet 7 0f 7 US 8,710,070 B2 oomomw“x22 3G- 21,98,,0be».,0?»_.03.b3.Ev.E8.0? mmicmow.wom.oN23Mmowvwo(.6166wewnmEzdamP092mt.mmm.r \0 INNS - m.@vm\$8 3mm1 x8 S| 18 13 wvmuE N.5 US 8,710,070 B2 1 OPIOID-KETAMINE AND NORKETAMINE CODRUG COMBINATIONS FOR PAIN MANAGEMENT 1'6 O X N This application claims priority from US. Provisional m T T \RZ Patent Application No. 61/072,090, ?led Mar. 27, 2008, the O O disclosure of which is hereby incorporated by reference in its entirety. wherein X is nothing, O, S, NH, NR4 (R4:alkyl), (CH2),C (where x:l-20, and the alkane moiety can be linear or FIELD OF THE INVENTION branched), and wherein R2-NiR3 is a norketamine moiety (R3:H) or a ketamine moiety (R3:CH3), and Rl-O is an The present invention relates to the ?eld of pain manage opioid moiety. ment, and more particularly to synergistic codrugs compris ing an opioid and ketamine or norketamine which have been In another embodiment, the present invention provides a combined to form a single chemical codrug entity. When the method of synthesis of a codrug comprising a linker, an codrug is administered it produces a synergistic analgesic opioid and a ketamine or a norketamine, said method com response to pain. prising: a) covalently bonding a ?rst attachment point of the linker to the opioid; b) covalently bonding a second attach BACKGROUND OF INVENTION ment point of the linker to the ketamine or norketamine; and 20 c) recovering the codrug, wherein the norketamine is selected Opioids are any endogenous or exogenous compounds that from the group consisting of S-norketamine, R-norketamine, bind to an opioid receptor. Opioid receptors are localized and racemic norketamine; and wherein the ketamine is primarily in the brain, spinal cord, and gastrointestinal tract. selected from the group consisting of S-ketamine, R-ket There are four broad groups of opioids: endogenous opioid amine, and racemic ketamine. peptides produced in the body; naturally occurring opioid 25 alkaloids such as morphine and codeine; semisynthetic opio In a further embodiment, the present invention provides a ids such as hydrocodone and oxycodone, and synthetic opio method of treatment comprising joining an opioid together ids such as fentanyl and methadone. When opioids bind to with a ketamine or a norketamine using a linker to form a their receptors in the brain and spinal cord they block pain cleavable codrug; and administering an analgesically effec transmission signals from the periphery of the body. Although tive amount of the codrug to a human patient, wherein the opioids are very effective for moderate to severe pain, there 30 norketamine is selected from the group consisting of S-nor are many well known problems associated with opioid ketamine, R-norketamine, and racemic norketamine and therapy. Those problems include serious side effects such as wherein the ketamine is selected from the group consisting of cognitive dysfunction, respiratory depression, nausea/vomit R-ketamine, S-ketamine and racemic ketamine. ing, urinary retention, and constipation. Further, chronic opioid therapy often results in the development of tolerance to 35 BRIEF DESCRIPTION OF THE DRAWINGS the analgesic effect (resulting in dose escalation) as well as physical and psychological dependence. FIG. 1 is a graph illustrating the effect of S-norketamine N-methyl-D-aspartate antagonists are known to be effec and morphine (MOR) combinations, using the tail ?ick test, tive in suppressing the symptoms of opiate withdrawal. The via intraperitoneal administration. FIG. 1A shows tail ?ick anesthetic ketamine is the most potent N-methyl-D-aspartate 40 latencies, and FIG. 1B shows the maximum possible effect. antagonist available in clinical practice. See, for example, FIG. 2 is a graph illustrating the effect of S-norketamine WO/2004/045601. There is a great need for analgesic medications able to and morphine (MOR) via the tail ?ick test, using intrathecal provide high e?icacy pain relief while providing more favor administration. FIG. 2A shows tail ?ick latencies, and FIG. able pharmacokinetics and reducing the possibility of unde 2B shows the maximum possible effect. 45 sirable effects. Therefore, there is a need for a way to admin FIG. 3 is a graph illustrating the effect of morphine (MOR) ister opioids and norketamine to provide a more favorable and with S-Norketamine (S-NK) using chronic constriction nerve pharmacokinetic pro?le.
Load more

Recommended publications
  • Ketamine As a Rapid Antidepressant
    BJPsych Advances (2016), vol. 22, 222–233 doi: 10.1192/apt.bp.114.014274 ARTICLE Ketamine as a rapid anti depressant: the debate and implications Roger C. M. Ho & Melvyn W. Zhang Roger Ho is an Associate Professor response rates to SSRIs and NaSSAs are around SUMMARY and consultant psychiatrist in 62% and 67% respectively (Papakostas 2008). the Department of Psychological Ketamine, a synthetic derivative of phencyclidine, Environmental factors such as relationship Medicine, Yong Loo Lin School of is a commonly misused party drug that is Medicine, National University of problems, financial difficulties and comorbid restricted in high-income countries because of Singapore. He has a special interest substance misuse often lead to poor treatment its addictive potential. Ketamine is also used as in psychoneuroimmunology and response, and antidepressants combined with the interface between medicine an anaesthetic in human and veterinary medicine. and psychiatry. Melvyn Zhang In the 1990s, research using ketamine to study the CBT have shown promising results in prevention is a senior resident with the pathophysiology of schizophrenia was terminated of mood disorders (Brenner 2010). Although 70– National Addiction Management owing to ethical concerns. Recently, controversy 90% of patients with depression achieve remission, Service, Institute of Mental Health, surrounding the drug has returned, as researchers around 10–30% are refractory to initial treatment Singapore. Correspondence Dr Roger C. M. have demonstrated that intravenous ketamine but respond to switching or combination of Ho, National University of Singapore, infusion has a rapid antidepressant effect and antidepressants, electroconvulsive therapy (ECT) Department of Psychological have therefore proposed ketamine as a novel or psychotherapy.
    [Show full text]
  • Misuse of Drugs Act (MEI 2013).Fm
    LAWS OF BRUNEI CHAPTER 27 MISUSE OF DRUGS 7 of 1978 9 of 1979 1984 Edition, Chapter 27 Amended by 10 of 1982 S 27/1982 S 20/1984 S 8/1987 S 36/1987 S 20/1989 S 24/1991 S 20/1992 S 28/1994 S 42/1998 S 60/1999 2001 Edition, Chapter 27 Amended by S 7/2002 S 59/2007 S 5/2008 S 12/2010 S 12/2012 REVISED EDITION 2013 B.L.R.O. 2/2013 LAWS OF BRUNEI Misuse of Drugs CAP. 27 1 LAWS OF BRUNEI REVISED EDITION 2013 CHAPTER 27 MISUSE OF DRUGS ARRANGEMENT OF SECTIONS Section PART I PRELIMINARY 1. Citation. 2. Interpretation. 2A. Appointment of Director and other officers of Bureau. 2B. Public servants. 2C. Powers of investigations of Bureau. 2D. Use of weapons. PART II OFFENCES INVOLVING CONTROLLED DRUGS 3. Trafficking in controlled drug. 3A. Possession for purpose of trafficking. 4. Manufacture of controlled drug. 5. Importation and exportation of controlled drug. B.L.R.O. 2/2013 LAWS OF BRUNEI 2 CAP. 27 Misuse of Drugs 6. Possession and consumption of controlled drug. 6A. Consumption of controlled drug outside Brunei Darussalam by permanent resident. 6B. Place of consumption need not be stated or proven. 7. Possession of pipes, utensils etc. 8. Cultivation of cannabis, opium and coca plants. 8A. Manufacture, supply, possession, import or export of equipment, materials or substances useful for manufacture of controlled drugs. 8B. Regulations and controlled substances. 9. Responsibilities of owners and tenants etc. 10. Abetments and attempts punishable as offences. 11.
    [Show full text]
  • Minnesota Statutes 1979 Supplement
    MINNESOTA STATUTES 1979 SUPPLEMENT 152.01 PROHIBITED DRUGS CHAPTER 152. PROHIBITED DRUGS Sec. 152.01 Definitions. 152.02 Schedules of controlled substances; admin­ istration of chapter. 152.01 Definitions. [For text of subds 1 to 8, see M.S.1978] Subd. 9. Marijuana. "Marijuana" means all parts of the plant of any species of the genus Cannabis, including all agronomical varieties, whether growing or not; the seeds thereof; the resin extracted from any part of such plant; and every compound, manufacture, salt, derivative, mixture, or preparation of such plant, its seeds or resin, but shall not include the mature stalks of such plant, fiber from such stalks, oil or cake made from the seeds of such plant, any other compound, manufacture, salt, derivative, mix­ ture, or preparation of such mature stalks, except the resin extracted therefrom, fiber, oil, or cake, or the sterilized seed of such plant which is incapable of germination. [For text of subds 10 to 17, see M.S.1978] [ 1979 c 157 s 1 ] 152.02 Schedules of controlled substances; administration of chapter. [For text of subd 1, see M.S.1978) Subd. 2. The following items are listed in Schedule I: (1) Any of the following substances, including their isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, unless specifically excepted, whenever the exis­ tence of such isomers, esters, ethers and salts is possible within the specific chemical des­ ignation: Acetylmethadol; Allylprodine; Alphacetylmethadol; Alphameprodine; Alpham- ethadol; Benzethidine; Betacetylmethadol; Betameprodine; Betamethadol; Betaprodine; Clonitazene; Dextromoramide; Dextrorphan; Diampromide; Diethyliambutene; Dime- noxadol; Dimepheptanol; Dimethyliambutene; Dioxaphetyl butyrate; Dipipanone; Ethylmethylthiambutene; Etonitazene; Etoxeridine; Furethidine; Hydroxypethidine; Ke- tobemidone; Levomoramide; Levophenacylmorphan; Morpheridine; Noracymethadol; Norlevorphanol; Normethadone; Norpipanone; Phenadoxone; Phenampromide; Pheno- morphan; Phenoperidine; Piritramide; Proheptazine; Properidine; Racemoramide; Tri­ meperidine.
    [Show full text]
  • Case Discussions in Palliative Medicine Levorphanol For
    JOURNAL OF PALLIATIVE MEDICINE Volume 21, Number 3, 2018 Case Discussions in Palliative Medicine ª Mary Ann Liebert, Inc. DOI: 10.1089/jpm.2017.0475 Feature Editor: Craig D. Blinderman Levorphanol for Treatment of Intractable Neuropathic Pain in Cancer Patients Akhila Reddy, MD,1,* Amy Ng, MD,1,* Tarun Mallipeddi,2 and Eduardo Bruera, MD1 Abstract Neuropathic pain in cancer patients is often difficult to treat, requiring a combination of several different pharmacological therapies. We describe two patients with complex neuropathic pain syndromes in the form of phantom limb pain and Brown-Sequard syndrome who did not respond to conventional treatments but re- sponded dramatically to the addition of levorphanol. Levorphanol is a synthetic strong opioid that is a potent N- methyl-d-aspartate receptor antagonist, mu, kappa, and delta opioid receptor agonist, and reuptake inhibitor of serotonin and norepinephrine. It bypasses hepatic first-pass metabolism and thereby not subjected to numerous drug interactions. Levorphanol’s unique profile makes it a potentially attractive opioid in cancer pain man- agement. Keywords: Brown-Sequard syndrome; cancer; cancer pain; levorphanol; neuropathic pain; phantom limb pain Introduction changes, structural reorganization of spinal cord and primary somatosensory cortex, and increased sensitization of spinal ne-third of cancer patients who experience pain cord may be the neurological basis for PLP.8,9 Because the Oalso experience neuropathic pain1 and about half the pathophysiology of PLP is not clearly understood, the treat- patients with cancer who suffer from neuropathic pain also ment options are mainly based on clinical experience.9 There have nociceptive pain.2 Most neuropathic pain exists as are case series showing that tramadol and methadone may be mixed pain in combination with nociceptive pain.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 9,687,445 B2 Li (45) Date of Patent: Jun
    USOO9687445B2 (12) United States Patent (10) Patent No.: US 9,687,445 B2 Li (45) Date of Patent: Jun. 27, 2017 (54) ORAL FILM CONTAINING OPIATE (56) References Cited ENTERC-RELEASE BEADS U.S. PATENT DOCUMENTS (75) Inventor: Michael Hsin Chwen Li, Warren, NJ 7,871,645 B2 1/2011 Hall et al. (US) 2010/0285.130 A1* 11/2010 Sanghvi ........................ 424/484 2011 0033541 A1 2/2011 Myers et al. 2011/0195989 A1* 8, 2011 Rudnic et al. ................ 514,282 (73) Assignee: LTS Lohmann Therapie-Systeme AG, Andernach (DE) FOREIGN PATENT DOCUMENTS CN 101703,777 A 2, 2001 (*) Notice: Subject to any disclaimer, the term of this DE 10 2006 O27 796 A1 12/2007 patent is extended or adjusted under 35 WO WOOO,32255 A1 6, 2000 U.S.C. 154(b) by 338 days. WO WO O1/378O8 A1 5, 2001 WO WO 2007 144080 A2 12/2007 (21) Appl. No.: 13/445,716 (Continued) OTHER PUBLICATIONS (22) Filed: Apr. 12, 2012 Pharmaceutics, edited by Cui Fude, the fifth edition, People's Medical Publishing House, Feb. 29, 2004, pp. 156-157. (65) Prior Publication Data Primary Examiner — Bethany Barham US 2013/0273.162 A1 Oct. 17, 2013 Assistant Examiner — Barbara Frazier (74) Attorney, Agent, or Firm — ProPat, L.L.C. (51) Int. Cl. (57) ABSTRACT A6 IK 9/00 (2006.01) A control release and abuse-resistant opiate drug delivery A6 IK 47/38 (2006.01) oral wafer or edible oral film dosage to treat pain and A6 IK 47/32 (2006.01) substance abuse is provided.
    [Show full text]
  • SENATE BILL No. 52
    As Amended by Senate Committee Session of 2017 SENATE BILL No. 52 By Committee on Public Health and Welfare 1-20 1 AN ACT concerning the uniform controlled substances act; relating to 2 substances included in schedules I, II and V; amending K.S.A. 2016 3 Supp. 65-4105, 65-4107 and 65-4113 and repealing the existing 4 sections. 5 6 Be it enacted by the Legislature of the State of Kansas: 7 Section 1. K.S.A. 2016 Supp. 65-4105 is hereby amended to read as 8 follows: 65-4105. (a) The controlled substances listed in this section are 9 included in schedule I and the number set forth opposite each drug or 10 substance is the DEA controlled substances code which has been assigned 11 to it. 12 (b) Any of the following opiates, including their isomers, esters, 13 ethers, salts, and salts of isomers, esters and ethers, unless specifically 14 excepted, whenever the existence of these isomers, esters, ethers and salts 15 is possible within the specific chemical designation: 16 (1) Acetyl fentanyl (N-(1-phenethylpiperidin-4-yl)- 17 N-phenylacetamide)......................................................................9821 18 (2) Acetyl-alpha-methylfentanyl (N-[1-(1-methyl-2-phenethyl)-4- 19 piperidinyl]-N-phenylacetamide)..................................................9815 20 (3) Acetylmethadol.............................................................................9601 21 (4) AH-7921 (3.4-dichloro-N-[(1- 22 dimethylaminocyclohexylmethyl]benzamide)...............................9551 23 (4)(5) Allylprodine...........................................................................9602
    [Show full text]
  • Prescription Drug Management
    Check out our new site: www.acllaboratories.com Prescription Drug Management Non Adherence, Drug Misuse, Increased Healthcare Costs Reports from the Centers for DiseasePrescription Control and Prevention (CDC) say Drug deaths from Managementmedication overdose have risen for 11 straight years. In 2008 more than 36,000 people died from drug overdoses, and most of these deaths were caused by prescription Nondrugs. Adherence,1 Drug Misuse, Increased Healthcare Costs The CDC analysis found that nearly 40,000 drug overdose deaths were reported in 2010. Prescribed medication accounted for almost 60 percent of the fatalities—far more than deaths from illegal street drugs. Abuse of painkillers like ReportsOxyContin from and the VicodinCenters forwere Disease linked Control to the and majority Prevention of the (CDC) deaths, say deaths from according to the report.1 medication overdose have risen for 11 straight years. In 2008 more than 36,000 people died from drug overdoses, and most of these deaths were caused by prescription drugs. 1 A health economics study analyzed managed care claims of more than 18 million patients, finding that patients undergoing opioid therapyThe CDCfor chronic analysis pain found who that may nearly not 40,000 be following drug overdose their prescription deaths were regimenreported in 2010. Prescribed medication accounted for almost 60 percent of the fatalities—far more than deaths have significantly higher overall healthcare costs. from illegal street drugs. Abuse of painkillers like OxyContin and Vicodin were linked to the majority of the deaths, according to the report.1 ACL offers drug management testing to provide information that can aid clinicians in therapy and monitoring to help improve patientA health outcomes.
    [Show full text]
  • Opioid Receptorsreceptors
    OPIOIDOPIOID RECEPTORSRECEPTORS defined or “classical” types of opioid receptor µ,dk and . Alistair Corbett, Sandy McKnight and Graeme Genes encoding for these receptors have been cloned.5, Henderson 6,7,8 More recently, cDNA encoding an “orphan” receptor Dr Alistair Corbett is Lecturer in the School of was identified which has a high degree of homology to Biological and Biomedical Sciences, Glasgow the “classical” opioid receptors; on structural grounds Caledonian University, Cowcaddens Road, this receptor is an opioid receptor and has been named Glasgow G4 0BA, UK. ORL (opioid receptor-like).9 As would be predicted from 1 Dr Sandy McKnight is Associate Director, Parke- their known abilities to couple through pertussis toxin- Davis Neuroscience Research Centre, sensitive G-proteins, all of the cloned opioid receptors Cambridge University Forvie Site, Robinson possess the same general structure of an extracellular Way, Cambridge CB2 2QB, UK. N-terminal region, seven transmembrane domains and Professor Graeme Henderson is Professor of intracellular C-terminal tail structure. There is Pharmacology and Head of Department, pharmacological evidence for subtypes of each Department of Pharmacology, School of Medical receptor and other types of novel, less well- Sciences, University of Bristol, University Walk, characterised opioid receptors,eliz , , , , have also been Bristol BS8 1TD, UK. postulated. Thes -receptor, however, is no longer regarded as an opioid receptor. Introduction Receptor Subtypes Preparations of the opium poppy papaver somniferum m-Receptor subtypes have been used for many hundreds of years to relieve The MOR-1 gene, encoding for one form of them - pain. In 1803, Sertürner isolated a crystalline sample of receptor, shows approximately 50-70% homology to the main constituent alkaloid, morphine, which was later shown to be almost entirely responsible for the the genes encoding for thedk -(DOR-1), -(KOR-1) and orphan (ORL ) receptors.
    [Show full text]
  • Recommended Methods for the Identification and Analysis of Fentanyl and Its Analogues in Biological Specimens
    Recommended methods for the Identification and Analysis of Fentanyl and its Analogues in Biological Specimens MANUAL FOR USE BY NATIONAL DRUG ANALYSIS LABORATORIES Laboratory and Scientific Section UNITED NATIONS OFFICE ON DRUGS AND CRIME Vienna Recommended Methods for the Identification and Analysis of Fentanyl and its Analogues in Biological Specimens MANUAL FOR USE BY NATIONAL DRUG ANALYSIS LABORATORIES UNITED NATIONS Vienna, 2017 Note Operating and experimental conditions are reproduced from the original reference materials, including unpublished methods, validated and used in selected national laboratories as per the list of references. A number of alternative conditions and substitution of named commercial products may provide comparable results in many cases. However, any modification has to be validated before it is integrated into laboratory routines. ST/NAR/53 Original language: English © United Nations, November 2017. All rights reserved. The designations employed and the presentation of material in this publication do not imply the expression of any opinion whatsoever on the part of the Secretariat of the United Nations concerning the legal status of any country, territory, city or area, or of its authorities, or concerning the delimitation of its frontiers or boundaries. Mention of names of firms and commercial products does not imply the endorse- ment of the United Nations. This publication has not been formally edited. Publishing production: English, Publishing and Library Section, United Nations Office at Vienna. Acknowledgements The Laboratory and Scientific Section of the UNODC (LSS, headed by Dr. Justice Tettey) wishes to express its appreciation and thanks to Dr. Barry Logan, Center for Forensic Science Research and Education, at the Fredric Rieders Family Founda- tion and NMS Labs, United States; Amanda L.A.
    [Show full text]
  • DEMAND REDUCTION a Glossary of Terms
    UNITED NATIONS PUBLICATION Sales No. E.00.XI.9 ISBN: 92-1-148129-5 ACKNOWLEDGEMENTS This document was prepared by the: United Nations International Drug Control Programme (UNDCP), Vienna, Austria, in consultation with the Commonwealth of Health and Aged Care, Australia, and the informal international reference group. ii Contents Page Foreword . xi Demand reduction: A glossary of terms . 1 Abstinence . 1 Abuse . 1 Abuse liability . 2 Action research . 2 Addiction, addict . 2 Administration (method of) . 3 Adverse drug reaction . 4 Advice services . 4 Advocacy . 4 Agonist . 4 AIDS . 5 Al-Anon . 5 Alcohol . 5 Alcoholics Anonymous (AA) . 6 Alternatives to drug use . 6 Amfetamine . 6 Amotivational syndrome . 6 Amphetamine . 6 Amyl nitrate . 8 Analgesic . 8 iii Page Antagonist . 8 Anti-anxiety drug . 8 Antidepressant . 8 Backloading . 9 Bad trip . 9 Barbiturate . 9 Benzodiazepine . 10 Blood-borne virus . 10 Brief intervention . 11 Buprenorphine . 11 Caffeine . 12 Cannabis . 12 Chasing . 13 Cocaine . 13 Coca leaves . 14 Coca paste . 14 Cold turkey . 14 Community empowerment . 15 Co-morbidity . 15 Comprehensive Multidisciplinary Outline of Future Activities in Drug Abuse Control (CMO) . 15 Controlled substance . 15 Counselling and psychotherapy . 16 Court diversion . 16 Crash . 16 Cross-dependence . 17 Cross-tolerance . 17 Custody diversion . 17 Dance drug . 18 Decriminalization or depenalization . 18 Demand . 18 iv Page Demand reduction . 19 Dependence, dependence syndrome . 19 Dependence liability . 20 Depressant . 20 Designer drug . 20 Detoxification . 20 Diacetylmorphine/Diamorphine . 21 Diuretic . 21 Drug . 21 Drug abuse . 22 Drug abuse-related harm . 22 Drug abuse-related problem . 22 Drug policy . 23 Drug seeking . 23 Drug substitution . 23 Drug testing . 24 Drug use .
    [Show full text]
  • LAAM in the Treatment of Opiate Addiction: Treatment Improvement Protocol (TIP) Series 22
    TIP 22: LAAM in the Treatment of Opiate Addiction: Treatment Improvement Protocol (TIP) Series 22 A43664 Ira J. Marion, M.A. Consensus Panel Chair U.S. Department of Health and Human Services Public Health Service Substance Abuse and Mental Health Services Administration Center for Substance Abuse Treatment Rockwall II, 5600 Fishers Lane Rockville, MD 20857 DHHS Publication No. (SMA) 95-3052 Printed 1995. Disclaimer This publication is part of the Substance Abuse Prevention and Treatment Block Grant technical assistance program. All material appearing in this volume except quoted passages from copyrighted sources is in the public domain and may be reproduced or copied without permission from the Center for Substance Abuse Treatment (CSAT) or the authors. Citation of the source is appreciated. This publication was written under contract number ADM 270-91-0007 from the Center for Substance Abuse Treatment of the Substance Abuse and Mental Health Services Administration (SAMHSA). Sandra Clunies, M.S., served as the CSAT Government project officer. Robert A. Lubran, M.S., M.P.A., was the Government content advisor. Carolyn Davis, Constance Gartner, Linda Harteker, Lise Markl, Barbara Shapiro, and Deborah Shuman served as writers. The opinions expressed herein are the views of the consensus panel members and do not reflect the official position of CSAT or any other part of the U. S. Department of Health and Human Services (DHHS). No official support or endorsement of CSAT or DHHS for these opinions or for particular instruments or software that may be described in this document is intended or should be inferred. The guidelines proffered in this document should not be considered as substitutes for individualized patient care and treatment decisions.
    [Show full text]
  • Picquestion of the Week:1/09/12
    Grand Teton, Wyoming USA PIC QUESTION OF THE WEEK: 1/09/12 Q: Can fentanyl be prescribed for a patient allergic to codeine? A: Opioid analgesics are among the most commonly prescribed drugs in the United States. True allergic reactions to opioid analgesics are extremely rare, dependent upon antibody (usually IgE/IgG), and triggered by histamine and other mediators. Immediate reactions (e.g. anaphylaxis) are associated with contraction of smooth muscle, vasodilation, increased mucous secretion, and enhanced vasopermeability. More frequently, opioids such as morphine and codeine cause direct release of histamine from mast cells. These reactions are considered idiosyncratic, independent of antibody, and based on individual patient susceptibility. Direct release of histamine is the most common mechanism for the development of urticaria, pruritus, etc. in patients receiving natural opioids such as morphine and codeine. Opioid analgesics are typically classified according to the source of the chemical or the presence of structurally related groups (see table). In general, the risk of cross-reactivity is thought to be less likely among agents from a different source or structural class. If a reaction to morphine or codeine is severe in nature, substituting a synthetic or semi-synthetic agent or a structurally dissimilar compound appears to reduce the risk of cross-reactivity. It should be noted that although tramadol is classified as a synthetic opioid derivative, there have been cases of severe hypersensitivity reactions associated with its use. These cases have occurred in patients with and without a history of allergic reactions to opiates. Thus tramadol would probably not a good first alternative in a patient with a history of a severe reaction to this group of drugs.
    [Show full text]